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Abstract
Background:  Aortic distensibility (AD) is a marker of the elastic properties of the aorta.
Reduction of AD occurs early in subjects with type 2 diabetes mellitus (T2DM) and it is associated
with subclinical generalized atherosclerosis. Metabolic syndrome (MetS) is common in subjects
with T2DM and predicts cardiovascular morbidity and mortality. This study examined the potential
relationship between MetS and AD in a cohort of subjects with T2DM.
Methods and results: A total of 210 subjects with T2DM were studied. MetS was diagnosed using
the NCEP/ATP-III criteria. AD was assessed non-invasively by ultrasonography. The prevalence of
MetS was 64.8%. AD was not significantly different between subjects with and without MetS (1.80
± 0.54 vs. 1.84 ± 0.53 10-6 dyn-1 cm2, p = 0.55). Univariate linear regression analysis showed that
AD was associated positively with male sex (p = 0.02) as well as glomerular filtration rate (p <
0.001), and negatively with age (p = 0.04), history of hypertension (p = 0.001), as well as duration
of diabetes (p < 0.001). After multivariate adjustment, AD was associated independently and
significantly only with age (p = 0.02), duration of diabetes p < 0.001), and history of hypertension
(p = 0.004); no significant relationship was found with MetS status, the sum of the components of
the MetS or the individual components-besides hypertension-of the MetS.
Conclusion: In subjects with T2DM, MetS status per se is not associated with reduction of AD. In
addition, it was shown that besides ageing, duration of glycemia was a strong predictor of AD. From
the components of the MetS only hypertension was associated with reduction of the elastic
properties of the aorta.
Background
Patients with type 2 diabetes mellitus (T2DM) suffer
often from macrovascular complications [1] while
cardiovascular morbidity and mortality is particularly
common in this group of patients [2]. Previous studies
have shown that aortic distensibility (AD), an index of
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aortic elasticity, is lower in individuals with T2DM in
comparison with age- and sex-matched nondiabetic coun-
terparts [3]. AD can be determined with high accuracy
non-invasively using ultrasonography [4] and is consid-
ered an index of the total arterial stiffness and an impor-
tant cardiovascular risk factor [5].
Metabolic syndrome (MetS) is defined as the clustering of
cardiovascular risk factors such as increased blood pres-
sure, insulin resistance, dyslipidaemia, central obesity,
high triglyceride and low high density lipoprotein (HDL)
cholesterol concentrations [6]. Presence of MetS is associ-
ated with increased risk for cardiovascular morbidity and
mortality [7] as well as development of T2DM [8]. Two
recently published studies have shown that in the general
population MetS is associated with increased carotid
intima-media thickness (IMT) [9] and pulse wave velocity
(PWV) [10], which reflect structural and functional prop-
erties of the arteries, respectively. However, the effect of
MetS on the elastic properties of the arteries in subjects
with T2DM is not well known. This cross-sectional study
examined the potential association between AD and MetS
in a cohort of T2DM subjects.
Methods
Subjects
A total of 210 subjects with T2DM, consecutively selected
from the diabetes outpatient clinic of our hospital were
enrolled into the study. Diagnosis of diabetes was based
on the American Diabetes Association criteria [11]. A
detailed history for the presence of cardiovascular disease,
current medication, information about other diseases and
smoking habits was obtained, and a thorough physical
examination was performed.
All measurements were performed in the morning, after
10–12 hours fast. The subjects were advised not to eat,
smoke, or drink coffee before examination. Blood sam-
ples were drawn for measurement of plasma glucose, gly-
cosylated haemoglobin A1c (HbA1c), creatinine, and lipid
profile. The antidiabetic medications were given to the
patients at the end of the examination. The purpose of the
study was clearly explained to all subjects, who then vol-
unteered to participate. The ethics committee of our hos-
pital approved the study and informed written consent
was obtained.
Blood pressure was measured three consecutive times, one
minute in apart, in the sitting position using an appropri-
ate cuff size. The mean values of the last two measure-
ments was calculated and used in the analysis. Arterial
hypertension was defined according to the current guide-
lines [12], when systolic was ≥ 140 mm Hg or and/or
diastolic blood pressure was ≥ 90 mm Hg or when the
patients were on antihypertensive treatment. In addition
the type of the antihypertensive treatment was recorded.
Of the study subjects 21.2% was on treatment with
angiotensin-converting enzyme inhibitors (ACE-I) and/or
angiotensin II receptor blockers (ARBs), 4.3% on diuret-
ics, 7.1% on β-blockers, and 9% on calcium channel
blockers. Coronary artery disease was defined as presence
of angina, history of previous myocardial infarction, pos-
itive stress testing, revascularization procedures or steno-
sis > 50% at the coronary arteries. Direct fundoscopy was
performed in all patients through dilated pupils.
Body weight with subjects in light clothing without shoes
and height was measured and body mass index (BMI) was
calculated. Waist circumference was measured with a soft
tape on standing, midway between the lowest rib and the
iliac crest. Hip circumference was measured over the wid-
est part of the gluteal region, and then the waist-to-hip
ratio (WHR) was calculated.
Definition of the MetS
Subjects having three or more of the following criteria,
according to the National Cholesterol Education Pro-
gram/Adult Treatment Panel III (NCEP/ATP III) report
[12], were defined as having the MetS: abdominal obesity
(waist circumference > 102 cm in men and > 88 cm in
women), triglycerides ≥ 1.7 mmol/L, low HDL choles-
terol: ≤ 1.0 mmol/L in men and ≤ 1.3 mmol/L in women,
high blood pressure: ≥ 130/85 mm Hg or use of antihy-
pertensive drugs and high fasting plasma glucose: ≥ 6.1
mmol/L or diagnosed diabetes mellitus.
Analytical methods
Fasting serum glucose, lipids and creatinine concentra-
tions were measured on a Technicon analyzer RA-XT. Low
density lipoprotein (LDL) cholesterol concentrations
were calculated using the Friedewald formula [13]. HbA1c
was measured by high-performance liquid chromatogra-
phy (HPLC) (Roche Diagnostics, Mannheim, Germany)
with a non-diabetic reference range of 4.0–6.0%. Micro-
albuminuria was assessed by measuring the albumin-to-
creatinine ratio (ACR) in a random urine sample on a
DCA 2000 analyzer using the immunonephelometry
technique (Bayer HealthCare LLC, Elkhart, USA). Glomer-
ular filtration rate (GFR) was calculated using the Modifi-
cation of Diet in Renal Disease formula [14]. Plasma
insulin was measured with radioimmunoassay (Biosure,
Belgium; c.v. = 3.3 ± 1.2%). Insulin resistance was esti-
mated using the homeostasis model assessment equation
of insulin resistance (HOMA-IR) [15].
Determination of AD
AD was determined non-invasively based on the relation-
ship between changes in aortic diameter and pressure
with each cardiac pulse [4]. The echocardiographic study
was carried out using a Hewlett Packard Sonos 1000 ultra-Cardiovascular Diabetology 2008, 7:1 http://www.cardiab.com/content/7/1/1
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sound system (Hewlett Packard, USA), using a 2.5 MHz
transducer. Each subject was placed in the mild left recum-
bent position and the ascending aorta was recorded at a
level 3 cm above the aortic valve in the M-mode tracings
guided by the two-dimensional echocardiogram in the
parasternal long axis view [4]. Internal aortic diameters
were measured by means of a caliper in systole and dias-
tole as the distance between the trailing edge of the ante-
rior aortic wall and the leading edge of the posterior aortic
wall. Systolic aortic diameter was measured as the maxi-
mal anterior motion of the aorta and diastolic diameter at
the peak of the QRS complex on the simultaneously
recorded electrocardiogram. Blood pressure was meas-
ured three consecutive times, one minute in apart at the
heart level during echocardiographic examination; the
mean values of the last two measurements was calculated
and used in the analysis. In addition, aortic diameter was
measured for ten consecutive cardiac beats routinely and
averaged. AD was calculated according to the formula
[4,16]:
, where
ΔD is the change of the aortic diameter between systole
and diastole, Dd is the aortic diameter in diastole, Ps is the
systolic and Pd is the diastolic blood pressure.
All measurements were performed by the same experi-
enced cardiologist, who was blind for the status of the par-
ticipants. The intraobserver coefficient of variation was
examined in our laboratory in 20 randomly selected
healthy subjects and was 4.2% for the systolic and 4.1%
for the diastolic aortic dimensions, respectively (not sig-
nificant differences).
The intra-observer mean percentage error (absolute differ-
ence between two observations divided by the mean and
expressed as percentage) was determined for the AD in 20
randomly selected subjects and was 7.5% in our center.
Statistical analysis
Statistical analysis was preformed using programs availa-
ble in the SPSS statistical package (SPSS 12.0, Chicago,
USA). All variables were tested for normal distribution of
the data. Data are shown as mean ± SD, unless it is stated
otherwise. A two sample t-test was used to assess differ-
ences in continuous variables, while a chi-square test was
used for categorical variables. Univariate linear regression
analysis was performed to look for the relationship
between AD and the variables of interest in the sample
population. Then, multivariate linear regression analyses
were performed (backward stepwise method) to look for
independent associations between AD and the variables
of interest. A total of 7 models of multivariate linear
regression analysis have been created. Model 1 (core
model) included the variables that were found to be
associated significantly with AD in univariate analysis and
included age, sex, duration of diabetes, history of hyper-
tension, and GFR; models 2–7 included the variables of
the core model and, in addition, MetS status (model 2),
the sum of the components of the MetS (model 3), high
waist circumference (model 4), low HDL cholesterol
(model 5), high triglycerides (model 6), and high blood
pressure (model 7). All independent variables in the mul-
tivariate analyses models were tested for multicolinearity.
P  < 0.05 (two-tailed) was considered statistically
significant.
Results
Prevalence rate of MetS was 64.8% in the study group.
Patients with and without MetS did not differ in terms of
age and sex. Diabetic patients with MetS had higher values
of waist, WHR, blood pressure, triglycerides, GFR, and
lower HDL cholesterol values in comparison with the dia-
betic subjects without the MetS. In addition, those with
MetS had more often hypertension and microalbuminu-
ria (Table 1). Moreover, diabetic patients with MetS were
more insulin resistant, although the difference was not
statistically significant (Table 1).
AD values was not different between diabetic patients
with and without the MetS (1.80 ± 0.54 vs. 1.84 ± 0.53 10-
6 dyn-1 cm2, p = 0.55). Moreover, women with diabetes
had significantly lower values of AD than diabetic men
(1.74 ± 0.36 vs. 1.86 ± 0.41 10-6 dyn-1 cm2, p = 0.02). Fur-
thermore, patients with, in comparison with those with-
out history of hypertension, had lower AD (1.76 ± 0.18 vs.
1.87 ± 0.20 10-6 dyn-1 cm2, respectively, p = 0.001).
Univariate linear regression analysis showed that AD was
associated significantly with sex [male vs. female, stand-
ardized regression coefficient (beta) = 0.15, p = 0.02), age
(beta = -0.14, p = 0.04), history of hypertension (beta = -
0.27, p = 0.001), duration of diabetes (beta = -0.49, p <
0.001), and GFR (beta = 0.33, p < 0.001). Concerning the
relationship between AD and the MetS status or the par-
ticular components of the MetS, the same analysis showed
no significant association between AD and MetS status (p
= 0.55) or the following components of the MetS: high
waist circumference [n = 124 (59.0%), p = 0.21), low HDL
cholesterol levels [n = 127 (60.5%), p = 0.33], and high
triglycerides levels [n = 82 (39.0)%, p = 0.55]; however,
there was a suggestive association with high blood pres-
sure [n = 165 (78.6%), beta = -0.13, p = 0.07] and with the
sum of the components of the MetS (beta = -0.14, p =
0.054). In addition, no any significant association was
found with smoking status (p = 0.48), BMI (p = 0.96),
HbA1c (p = 0.44), presence of retinopathy (p = 0.26), ACR
(p = 0.43), HOMA-IR (p = 0.98), use of statins (p = 0.89),
and use of various classes of antihypertensive medications
Aortic distensibility  dyn  cm = ⋅−
−− 2 10
61 2 ΔD
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like ACE-I/ARBs, β-adrenergic blockers, calcium channel
blockers or diuretics (all p > 0.05).
Multivariate linear regression analysis demonstrated, after
controlling for GFR, significant independent associations
between AD and age (p = 0.02), duration of diabetes (p <
0.001), and history of hypertension (p = 0.004) and a sug-
gestive association with sex (p = 0.08). These variables
explained 34% of the variance of AD. No any significant
relationship was found with MetS status, sum of the com-
ponents of the MetS, or with the individual components-
besides hypertension-of the MetS (Table 2).
Discussion
Prevalence of MetS in T2DM
As expected and in agreement with previous reports,
the present study showed that MetS is common (64.8%)
among subjects with T2DM [17]. Even higher rates (75–
78%) of MetS in diabetic subjects have been described
previously [18,19]. Published data on the prevalence
of MetS among subjects with diabetes in Greece are
limited [20].
MetS and early atherosclerosis in diabetes
The main finding of the present study is that in patients
with T2DM, AD is not different between those with and
without MetS and that diabetes-related factors, like dura-
tion of the disease as well as hypertension, are strongly
associated with AD. This finding suggests that, from the
clinical point of view, presence of MetS per se does not add
information in the identification of early atherosclerosis
in patients with T2DM.
One recent large-scale study demonstrated that although
MetS was associated with marginally higher carotid artery
stiffness in patients with clinical manifestations of arterial
disease, after multivariate adjustment, the relationship
between carotid stiffness and MetS waned, while diabetes
status emerged as independent predictor of carotid artery
stiffness [21]. Another study in Indigenous Australians
showed that diabetes status and some of the components
of the MetS were associated with carotid artery IMT in this
high-risk population for cardiovascular disease mortality
[22]. In addition, recent data demonstrated that although
intensive diabetes control was associated with higher
Table 1: Demographic and clinical characteristics of the study subjects stratified according to the presence (MetS+) or not (MetS-) of 
metabolic syndrome
MetS (-) MetS (+) p
n (%) 74 (35.2) 136 (64.8) -
Males/females n (%) 35 (52.7)/39 (47.3) 72 (52.9)/64 (47.1) 0.98
Age (years) 59.9 ± 7.4 60.8 ± 8.4 0.43
Body mass index (kg/m2) 27.6 ± 4.8 28.8 ± 5.78 0.12
Waist (cm) 94.8 ± 11.1 103.9 ± 11.5 <0.001
Waist-to-hip ratio 0.91 ± 0.08 0.95 ± 0.069 <0.001
Systolic blood pressure (mm Hg) 128.2 ± 22.7 142.9 ± 18.4 <0.001
Diastolic blood pressure (mm Hg) 74.38 ± 12.66 81.05 ± 11.32 <0.001
Pulse pressure (mm Hg) 53.8 ± 17.0 61.2 ± 15.8 0.008
Glucose (mmol/l) 9.37 ± 3.46 9.12 ± 2.68 0.63
Total cholesterol (mmol/l) 5.55 ± 1.14 5.67 ± 1.29 0.52
HDL cholesterol (mmol/l) 1.33 ± 0.33 1.03 ± 0.22 <0.001
LDL cholesterol (mmol/l) 3.66 ± 1.03 3.71 ± 1.09 0.91
Triglycerides (mmol/l) 1.14 ± 0.42 1.98 ± 1.04 <0.001
GFR (ml/min/1.73 m2) 99.7 ± 26.8 107.5 ± 38.9 0.35
HOMA-IR* 3.7 (2.5–6.1) 4.9 (3.2–8.3) 0.10
Duration of diabetes (years) 10.28 ± 5.93 11.53 ± 8.78 0.31
HbA1c (%) 7.78 ± 1.68 7.55 ± 1.74 0.35
Hypertension (yes) n (%) 25 (47.2) 69 (68.3) 0.03
CAD (yes) n (%) 4 (8) 12 (12.9) 0.24
Use of stains (yes) n (%) 9 (12.2) 35 (25.7) 0.02
Any retinopathy (yes) n (%) 5 (6.8) 19 (14.5) 0.08
Microalbuminuria (yes) n (%) 16 (32) 47 (51.1) 0.01
Treatment for diabetes n (%) 0.49
Diet alone 8 (10.8) 22 (16.4)
Antidiabetic tablets 54 (73) 88 (65.7)
Insulin 12 (16.2) 24 (17.9)
*Median values (interquartile range). p values for the comparison between groups with and without metabolic syndrome by independent samples t-
test for continuous variables, Mann-Whitney U test for ordinal data or by Pearson χ2 for nominal variables.
HDL: high density lipoprotein; LDL: low density lipoprotein; HOMA-IR: homeostasis model assessment insulin resistance; GFR: glomerular filtration 
rate; CAD: coronary artery disease.Cardiovascular Diabetology 2008, 7:1 http://www.cardiab.com/content/7/1/1
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prevalence of MetS in subjects with type 1 diabetes, glyc-
emic control, but not MetS status, predicted the develop-
ment of micro-and macro-vascular in this group of
patients [23]. Moreover, other data showed that cardio-
vascular or all-cause mortality was not different in sub-
jects with T2DM stratified according to MetS status [18],
and that MetS was not associated independently with cor-
onary artery disease, while diabetes status did [24]. Thus,
our data corroborate these reports showing that among
patients with T2DM, MetS per se is not associated with
macrovascular complications.
Diabetes-related factors are strongly associated with AD
Multivariate analysis demonstrated an independent rela-
tionship between AD and the known duration of diabetes.
A large body of evidence exists suggesting that diabetes
affects the functional properties of the aorta [25,26], over-
coming the potential effect of other cardiovascular risk
factors. Reduction of AD occurs early in patients with
T2DM, and one study showed that AD is low even in the
nondiabetic first degree relatives of patients with T2DM
[25]. Chronic exposure of the aorta to the effects of hyper-
glycaemia explains the detrimental effect of diabetes on
reduction of the elastic properties [25]. Non-enzymatic
glycation of matrix proteins caused by chronic hypergly-
caemia results in structural and functional changes of the
aorta [26,27]. Moreover, in vitro glycation of collagen and
elastin, and accumulation of advanced glycation end-
products have been shown to increase arterial stiffness
[26]. Furthermore, the present study has shown that dia-
betic women had stiffer aortas than diabetic men. This
finding is in accordance with previous reports showing
that diabetic women with either type 1 [28] or type 2 dia-
betes [29,30] have stiffer arteries in comparison with men
with diabetes.
The effect of hypertension on AD in diabetes
Besides duration of diabetes, history of hypertension was
an important determinant of AD. It is known that from
the traditional cardiovascular risk factors, hypertension is
much more common in subjects with T2DM. The UK Pro-
spective Diabetes Study demonstrated the importance of
the strict blood pressure control in the reduction of micro-
vascular and macrovascular complications in subjects
with T2DM [31]. The Multiple Risk Factor Intervention
Trial (MRFIT) showed that diabetic patients with
increased blood pressure had a two-fold higher annual
death rate in comparison with normotensive subjects [1].
Other studies demonstrated that blood pressure was the
strongest component of the MetS associated with reduc-
tion of the arterial elasticity [10,32]. Furthermore, in
agreement with previous reports we showed that ageing is
strongly associated with reduction of the elastic properties
of the aorta, irrespective of the presence of diabetes
[33,34].
It is noteworthy that patients with T2DM and MetS had
more often microalbuminuria in comparison with those
Table 2: Multivariate linear regression analysis: the association between various parameters with aortic distensibility in the study 
population.
B SE (B) beta p Adjusted R2
Independent variables
Model 1
Age (1 year) -0.004 0.002 -0.17 0.02
Sex (male vs. female) 0.046 0.026 0.12 0.08
Duration of diabetes (1 year) -0.009 0.002 -0.36 <0.001
History of hypertension (yes vs. 
no)
-0.080 0.027 -0.20 0.004 0.34
Model 2
MetS status (yes vs. no) -0.010 0.036 -0.019 0.78 0.33
Model 3
Sum of the components of the 
MetS
-0.015 0.013 -0.084 0.24 0.34
Model 4
High waist (yes vs. no) -0.036 0.029 -0.09 0.21 0.33
Model 5
Low HDL cholesterol (yes vs. no) -0.026 0.027 -0.09 0.33 0.33
Model 6
High triglycerides (yes vs. no) -0.017 0.029 -0.04 0.55 0.33
Model 7
High blood pressure (yes vs. no) -0.065 0.036 -0.13 0.07 0.34
Parentheses show the units of increment or the categories of the independent variables.
B: unstandardized regression coefficient; SE: standard error; beta: standardized regression coefficient; MetS: metabolic syndrome; HDL: high density 
lipoprotein. All models were adjusted in addition for glomerular filtration rate.Cardiovascular Diabetology 2008, 7:1 http://www.cardiab.com/content/7/1/1
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without MetS. This finding is not surprising, given that
microalbuminuria was included in the diagnostic criteria
for the MetS proposed by the World Health Organization
[35]. However, microalbuminuria was not associated with
AD in subjects with diabetes in either univariate or multi-
variate analysis, suggesting that, contrary to the non-dia-
betic population [32], diabetes may overcome the effect of
microalbuminuria on the elastic properties of the arteries.
Interestingly, despite the recommendations for low LDL
cholesterol and blood pressure levels in the patients with
diabetes, only a small percentage of them have been
treated with lipid lowering medications and only 12.8%
of those had LDL cholesterol levels < 2.6 mmol/l and
47.7% had systolic/diastolic blood pressure levels at the
recommended target < 130/80 mm Hg.
Limitations
Our study has some limitations. First, many diabetic
patients were on treatment with statins. Therefore, preva-
lence rate of dyslipidaemia and MetS may have been
underestimated in the diabetic group, although statins
lower mainly the LDL-cholesterol, which is not a compo-
nent of the MetS. Second, in this study aortic diameters
were measured echocardiographically. Previous studies
have shown that aortic diameter can be obtained with a
high degree of accuracy in subjects whose cardiothoracic
anatomy permits an echocardiographic signal of satisfac-
tory quality [4]. Moreover, the pulse pressure obtained by
external sphygmomanometer introduces an error factor,
but the final result in the validity of the aortic distensibil-
ity calculation is trivial [4].
Conclusion
In conclusion, our study showed that in subjects with
T2DM, MetS status per se is not associated with reduction
in AD. In addition, we showed that besides ageing, dura-
tion of glycemia was strong predictor of AD. From the
components of the MetS only hypertension was associ-
ated with reduction of the elastic properties of the aorta.
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